- Home
- JYD vs APRE Comparison
JYD vs APRE Comparison
Compare JYD & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$2.98
HOLD
Current Price
$0.94
Company Overview
Basic Information| Metric | JYD | APRE |
|---|---|---|
| Founded | 2001 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9M | 8.4M |
| IPO Year | 2022 | 2019 |
Fundamental Metrics
Financial Performance| Metric | JYD | APRE |
|---|---|---|
| Price | $2.98 | $0.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.10 |
| AVG Volume (30 Days) | 9.4K | ★ 308.7K |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.22 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.09 | $0.55 |
| 52 Week High | $6.85 | $2.22 |
Technical Indicators
Market Signals| Indicator | JYD | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 49.65 | 63.79 |
| Support Level | $2.42 | $0.90 |
| Resistance Level | $2.93 | $0.98 |
| Average True Range (ATR) | 0.11 | 0.09 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 69.96 | 91.00 |
Price Performance
Historical Comparison JYD
APRE
About JYD Jayud Global Logistics Limited
Jayud Global Logistics Ltd is an end-to-end supply chain solution provider in China, with a focus on providing cross-border logistics services. The company offers freight forwarding services, supply chain management, and other value-added services.
About APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.